FIELD: chemistry.
SUBSTANCE: present invention relates to a method for stimulating production of HBV-specific antibodies using a compound selected from: 6-amino-9-benzyl-N-methyl-8-oxo-N-propyl-2-(propylsulphonimidoyl)purine-7-carboxamide, 6-amino-9-[(4-chlorophenyl)methyl]-2-[S(R)-ethylsulphonimidoyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide, 6-amino-9-[(4-chlorophenyl)methyl]-2-[S(S)-ethylsulphonimidoyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide, 6-amino-9-[(4-chlorophenyl)methyl]-N-ethyl-2-[S(S)-ethylsulfonimidoyl]-N-methyl-8-oxo-purine-7-carboxamide, 6-amino-9-[(4-chlorophenyl)methyl]-N-ethyl-2-[S(R)-ethylsulphonimidoyl]-N-methyl-8-oxo-purine-7-carboxamide, 6-amino-2-[S(R)-ethylsulphonimidoyl]-N-methyl-8-oxo-N-propyl-9-(p-tolylmethyl)purine-7-carboxamide, 6-amino-2-[S(S)-ethylsulphonimidoyl]-N-methyl-8-oxo-N-propyl-9-(p-tolylmethyl)purine-7-carboxamide, 6-amino-N-ethyl-2-[S(S)-ethylsulphonimdoyl]-N-methyl-8-oxo-9-(p-tolylmethyl)purine-7-carboxamide, 6-amino-N-ethyl-2-[S(R)-ethylsulphonimidoyl]-N-methyl-8-oxo-9-(p-tolylmethyl)purine-7-carboxamide, 6-amino-2-(ethylsulphonimidoyl)-9-[(4-fluorophenyl)methyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide, 6-amino-2-[S(R)-ethylsulphonimidoyl]-9-[(4-fluorophenyl)methyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide, 6-amino-2-[S(S)-ethylsulphonimidoyl]-9-[(4-fluorophenyl)methyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide, 6-amino-9-[(4-bromophenyl)methyl]-2-(ethylsulphonimidoyl)-N-methyl-8-oxo-N-propyl-purine-7-carboxamide, 6-amino-2-[S(R)-ethylsulphonimidoyl]-9-[(4-bromophenyl)methyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide, 6-amino-2-[S(S)-ethylsulphonimidoyl]-9-[(4-bromophenyl)methyl]-N-methyl-8-oxo-N-propyl-purine-7-carboxamide, 6-amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-(ethylsulphonimidoyl)-N-methyl-8-oxo-purine-7-carboxamide, 6-amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-[S(S)-(ethylsulphonimidoyl)]-N-methyl-8-oxo-purine-7-carboxamide, 6-amino-9-[(4-bromophenyl)methyl]-N-ethyl-2-[S(R)-(ethylsulphonimidoyl)]-N-methyl-8-oxo-purine-7-carboxamide or pharmaceutically acceptable salts thereof, enantiomers or diastereomers.
EFFECT: invention provides stimulation of production of HBV-specific antibodies.
1 cl, 7 dwg, 14 tbl, 57 ex
Title | Year | Author | Number |
---|---|---|---|
7-SUBSTITUTED SULFONIMIDOYLPURINONES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION | 2017 |
|
RU2751349C2 |
NEW COMPOUNDS AND DERIVATIVES OF SULFONIMIDEOILPURINON FOR TREATMENT AND PROPHYLAXIS OF VIRAL INFECTION | 2016 |
|
RU2745269C2 |
PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | 2013 |
|
RU2661896C2 |
AZASPIROALKANE DERIVATIVES METALLOPROTEASE INHIBITORS | 2004 |
|
RU2379303C2 |
HETEROARYL COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF AS PROTEIN KINASE INHIBITORS | 2007 |
|
RU2474582C2 |
HYDROXYPURINE COMPOUNDS AND USE THEREOF | 2016 |
|
RU2685417C1 |
NMDA RECEPTOR MODULATORS AND THEIR APPLICATION | 2012 |
|
RU2621049C2 |
NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATION OF CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | 2015 |
|
RU2684396C2 |
PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | 2018 |
|
RU2764243C2 |
Authors
Dates
2025-04-18—Published
2017-08-28—Filed